Literature DB >> 3797808

Meperidine disposition in burn patients.

D C Bloedow, L A Goodfellow, J Marvin, D Heimbach.   

Abstract

Limited information is available describing the pharmacokinetics of hepatically-cleared drugs in burn patients. Based on the hypothesis that after burn injury, plasma meperidine clearance should increase in response to the postburn increase in hepatic blood flow, we examined the kinetics of intravenous meperidine in eleven patients about one week after burn injury (acute study) and in five of these patients about six weeks postburn (convalescent study). The meperidine steady-state distribution volume (about 2 1/kg) during both the acute and the convalescent studies was about half the distribution volume reported in the literature for meperidine in healthy subjects. The meperidine clearance in burn patients (acute, 420 ml/min and convalescent, 600 ml/min) was lower than would be anticipated in the presence of known marked increases in hepatic blood flow in burn patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3797808

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  4 in total

Review 1.  Pathophysiology and pharmacokinetics following burn injury.

Authors:  P L Bonate
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 2.  Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.

Authors:  B K Wagner; D A O'Hara
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

Review 3.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics in patients with burns.

Authors:  U Jaehde; F Sörgel
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.